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Monocytes and peritubular capillary C4d deposition in acute Complement split factor C4d is generated by the acti-
renal allograft rejection. vation of the classical complement pathway by antigen-
Background. Peritubular capillary (PTC) deposition of com- antibody complexes and binds covalently to tissue ele-plement split factor C4d in renal allografts has been shown to
ments at the site of activation. Deposition of C4d alongbe closely associated with circulating antidonor antibodies and
a marker for relatively poor graft survival. Monocyte/macro- peritubular capillaries (PTC) has been shown to be closely
phage (MO) infiltration of renal allografts has been shown to correlated with circulating donor-specific antibodies in
adversely affect graft survival. The purpose of this study was renal allograft recipients experiencing acute rejectionto assess whether the two phenomena are related.
and has been suggested as a marker for AHR [3, 5, 8].Methods. Twenty-three biopsies (from 15 patients) demon-
Several studies have addressed the issue of morpho-strated diffuse strong staining of PTC for C4d (C4d group)
and acute tubular injury with or without significant cellular re- logic markers of AHR [1, 5, 10]. The results of these inves-
jection, while 28 biopsies (with acute rejection) but negative tigations have emphasized the association of neutrophilicfor PTC C4d served as controls (C4d group).
infiltration in biopsies from patients with AHR [5, 10].Results. The C4d group demonstrated significantly greater
Other lesions that have been shown to be significantlyglomerular and interstitial MO infiltration than did the C4d
group [3.4  2.0 vs. 0.2  0.3 MO/glomerulus, P  0.0001; correlated with AHR include glomerular and arterial
12.9 9.2 vs. 6.5 5.0 MO/high power field (hpf), P 0.0030]. fibrinoid necrosis, vascular thrombosis, infarction, andNeutrophilic (PMN) infiltration of glomeruli and PTC was also
glomerulitis [5, 10]. In these studies, many of the biopsiessignificantly greater in the C4d group than in the C4d one
(0.8  0.6 vs. 0.3  0.3 PMN/glomerulus, P  0.0003; 0.9  from patients with AHR also demonstrated the histo-
0.8 vs. 0.4  0.3 PTC PMN/hpf, P  0.0035). logic features of acute cellular rejection (ACR), as de-
Conclusion. The results indicate a close association between fined by both the Banff and Cooperative Clinical TrialsPTC C4d deposition and MO infiltration, particularly glomeru-
in Transplantation (CCTT) criteria [1, 5, 10].lar, and confirm previous observations regarding the correla-
tion of PTC C4d staining and PMN infiltration. Glomerular and interstitial monocyte/macrophage (MO)
infiltration has been observed in biopsies demonstrating
ACR [11–20] and has been shown to be associated with
There has been considerable interest in acute humoral relatively poor allograft survival [11–16, 21]. As little
rejection (AHR) in recent years. This form of rejection mention has been made of MO in AHR, a detailed study
is often resistant to conventional antirejection therapy of biopsies demonstrating diffuse strong PTC C4d immu-
[1–4] and has been shown to carry a relatively poor long- nostaining and the morphologic features associated with
term prognosis [5–8]. Recent studies have suggested that AHR was performed to evaluate this phenomenon. The
unconventional therapeutic measures such as plasma ex-
results indicate that MO infiltration, particularly glomer-change [with tacrolimus-mycophenolate rescue or intra-
ular, is a significant feature of these biopsies and confirmvenous immune globulin (IVIG)] or immunoabsorption
previous observations of significantly increased glomeru-may be of benefit in AHR [2, 9], underlining the impor-
lar and PTC neutrophilic infiltration in these biopsiestance of recognizing AHR especially in allograft biopsies.
compared to those demonstrating ACR and no PTC C4d
reaction [5, 10].
1 See Editorial by Colvin, p. 1953.
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whose allograft biopsies demonstrated diffuse strong more than 50% of PTC showed strong circumferential
staining for C4d. For cross-study comparison purposes,PTC staining for C4d and histologic evidence of acute
tubular injury were included in the test group (C4d biopsies showing focal PTC C4d staining were not in-
cluded in this study.group). Twenty-three biopsies from 15 patients (10 fe-
males, 5 males) biopsied serially between January 1, 1999
Clinical monitoringand June 30, 2002 met these criteria. Twenty-eight serial
biopsies done between January 1, 1999 and December The patients’ serum panel reactive antibody (PRA)
level was determined by standard lymphocytotoxic assay31, 1999 from an unselected group of 24 patients (5 fe-
males, 19 males) with acute rejection by the Banff 97 prior to transplantation. Flow cytometric cross-match
(FACSCalibur G3 Flow Cytometer; Becton-Dickinson,criteria (at least grade 1A) [22] and no staining for PTC
C4d served as controls (ACR group). Patient and donor Franklin Lakes, NJ) was performed at the time of trans-
plantation in patients at high risk (PRA 30%) or indata were compiled primarily from the British Columbia
Transplant Society renal transplant database. Chart re- those receiving a second or greater transplant and was
used to detect circulating antidonor antibodies at theviews were performed when specific information was not
available from the database. time of rejection.
Initial immunosuppression was achieved using a stan-
Histology dard triple therapy regimen of methylprednisolone, 1 mg/
kg/day for 3 to 5 days, then prednisone, 0.7 to 1 mg/kg/Renal biopsies were divided into three portions for
light microscopy, electron microscopy, and immunohis- day, tapering to 0.3 mg/kg/day by 2 weeks posttransplant,
and 0.15 mg/kg/day by 6 months (all patients); and cyclo-tochemistry. For light microscopy, tissue was fixed in
either B5 fixative (50 biopsies) and embedded in paraffin sporine, 9.0 mg/kg/day adjusted for trough levels 425 to
500 ug/mL for the first 30 days, then tapered graduallyor Karnovsky’s fixative (two biopsies) and embedded in
polyglycol methacrylate. Sections embedded in paraffin to levels of 100 to 150 ug/L for long-term maintenance
(29 patients), or tacrolimus, 0.12 to 0.15 mg/kg/day ad-were cut at 2 m and stained with hematoxylin-eosin
(H&E), periodic acid-Schiff (PAS), and periodic acid- justed for trough levels 10 to 15 ug/mL for the first
30 days, then tapered gradually to levels of 5 to 8 ug/mLsilver methenamine (PASM). Sections embedded in po-
lyglycol methacrylate were cut at 1 m and stained with for long-term maintenance (11 patients) and mycophe-
nolate mofetil, 2000 mg/day (all patients). Induction ther-H&E and PASM. The biopsies were examined by one
of the authors (A.B.M.). apy was used in four patients at high risk (PRA 30%)
and consisted of a 7- to 10-day course of treatment with
Immunohistochemistry antilymphocyte antibodies (OKT3, Ortho Biotech, Rari-
tan, NJ, USA), 5 mg/day. All rejection episodes wereThe avidin-biotin peroxidase complex procedure for
antibody localization was used. Acetone-fixed sections of treated with methylprednisolone for 3 to 6 days (total dose
range 1500 mg to 4000 mg). Patients with Banff gradesnap-frozen renal tissue were stained with commercially
available mouse monoclonal antibodies specific for com- IIA or greater rejections were treated with OKT3 for
7 to 10 days (5 mg/day). One C4d patient had plasmaplement split factor C4d (Quidel, San Diego, CA, USA).
Snap-frozen sections from biopsies of membranous glo- exchange for two rejection episodes with a total of 10
exchanges for each episode and IVIG following themerulonephritis that showed strong glomerular staining
for C4d served as positive controls for C4d. Lymph node plasma exchange for the second episode. Another C4d
patient received IVIG. A full response to therapy wastissue was used as positive controls for CD68 and CD3.
B5-fixed paraffin-embedded sections were stained with a return of renal function to baseline prerejection creati-
nine. A partial response was defined as a decrease incommercially available mouse monoclonal antibodies spe-
cific for CD68 (a marker for MO) and CD3 (T-cell marker) creatinine of at least 20% from its peak but not to the
prerejection baseline level. Evaluation of graft survival(Dako, Carpinteria, CA, USA). For the two biopsies in
which the histologic portion had been embedded in poly- was not done because of the short follow-up periods in
some of the C4d patients.glycol methacrylate, acetone-fixed sections of snap-
frozen renal tissue were stained for CD68 and CD3 with
Quantitative analysiscommercially available mouse monoclonal antibodies
(Dako). Negative controls consisted of cases of thin base- All biopsies were scored according to the Banff 97
criteria [22] to determine the type and grade of the rejec-ment membrane disease. Additional control studies were
performed by omitting the primary monoclonal antibody tion reaction. Neutrophils (PMN), MO, and T cells were
counted in all glomeruli in each biopsy and expressedin the staining procedure and by using an irrelevant
mouse monoclonal antibody as the primary antibody. as the number of cells per glomerulus. The number of
cortical PTC PMN and cortical interstitial (CI) MO perThe biopsies were evaluated by one of the authors
(A.B.M.). A biopsy was considered positive for C4d if high power field (hpf) (40 objective with an object area
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Fig. 1. Immunohistochemistry for C4dGroup. (A) There is diffuse strong staining of peritubular capillaries for C4d. (B) The glomerulus contains
several CD68 cells (monocytes) (arrowheads). (C ) Numerous CD68 cells (monocytes) are present in the interstitium. The glomerulus (G)
contains a CD68 cell (arrowhead). (A) Magnification is 160; (B) and (C) Magnification is 260.
Table 1. Comparison of C4d and acute cellular rejection (ACR)diameter of 0.5 mm and an area of 0.196 mm2) in each
(C4d) groups with respect to biopsy findings
biopsy was determined by counting the number of corti-
Variable number C4d ACR P ccal PTC PMN, CI MO, and cortical hpfs using a high
Number of biopsies 23 28power objective (40) and dividing the number of cells
Glomerulitis % 13 (57) 3 (11) 0.0014by the number of cortical hpfs. For the quantitative anal-
Acute tubular injurya % 22 (96) 11 (39) 0.0001
yses only those biopsies with cortex containing a mini- Peritubular capillary
polymorphonuclear leukocyteb % 23 (100) 28 (100) NSmum of four glomeruli were used. Thus two C4d biop-
	2.0 peritubular capillarysies with three glomeruli were not included in the MO
polymorphonuclear leukocyteb % 2 (9) 0 NS
and T-cell count determinations. Glomerular polymorphonuclear
leukocyteb 22 (96) 26 (93) NS
	1.0 polymorphonuclear leukocyteb/Statistical analysis
glomeruli % 5 (22) 2 (7) 0.1193
Descriptive statistics are presented as mean  stan- Polymorphonuclear leukocyteb
tubulitis % 8 (35) 3 (11) 0.0823dard deviation (SD). Continuous variables were com-
Glomerular monocyte/macrophage % 22 (96) 12 (43) 0.0002pared using the t test and categorical variables were
Glomerular T cells % 18 (78) 23 (82) NS
compared using the chi square (
2) test. A P value of less
NS is not significant.
than 0.05 for two-sided univariate tests was considered a Acute tubular injury not associated with significant inflammation (i 	 2) or
tubulitis (t 	 2)significant.
b Neutrophil
c C4d vs. ACR, 
2 test
RESULTS
Renal biopsy findings
1) with either no, mild, or moderate tubulitis (Banff 97All but two of the 23 biopsies from the 15 patients
score: t 0, 1 or 2) or moderate interstitial inflammationwith strong diffuse PTC C4d staining (C4d group) (Fig.
(Banff 97 score: i  2) with no or mild tubulitis (Banff1) contained more than 10 glomeruli. The other two
97 score: t  0 or 1) and were graded as suspiciousbiopsies had nine glomeruli each. All of the C4d biop-
for cellular rejection according to the Banff 97 gradingsies had at least two interlobular arteries. Twenty of the
system [22]. Eight of the C4d biopsies also had acute28 biopsies with no PTC C4d staining (C4d group)
cellular interstitial rejection [Banff 97 grade 1A (N  5)contained 10 or more glomeruli, while eight had nine
or 2A (N  3)]. The C4d biopsies (ACR group) allglomeruli. Two of the C4d biopsies lacked interlobular
demonstrated significant ACR [Banff 97 grades 1A (Narteries. The mean intervals between the times of trans-
13), 1B (N  5), 2A (N  9), 3 (N  1)].plantation and times of biopsy for the C4d and the
The significant biopsy findings are summarized in Ta-C4d groups were 22  20 days and 31  43 days,
ble 1. Compared to the C4d group, the C4d grouprespectively, the difference not being significant.
showed significantly more glomerulitis (P  0.0003),The C4d biopsies could be divided into two sub-
acute tubular injury not associated with significant tubul-groups based on whether there was a significant cellular
itis (t 	 2) or inflammation (i 	 2) (P  0.0001) andcomponent to the acute rejection reaction or not. Fifteen
glomerular MO infiltration (Fig 1) (P  0.0001). Theof the C4d biopsies demonstrated either mild intersti-
tial mononuclear cellular infiltration (Banff 97 score: i sensitivity and specificity of glomerular MO infiltration
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Table 2. Results of quantitative analysis of biopsy findings for the C4d and the acute cellular rejection (ACR) (C4d) groups
Variable number C4d ACR P a
Polymorphonuclear leukocyte/glomerulus (range) 0.80.6 (0–3.1) 0.30.3 (0–1.4) 0.0003
Peritubular capillary polymorphonuclear leukocyte/
high power field (40) (range) 0.90.8 (0.1–3.5) 0.40.3 (0.1–1.1) 0.0035
Monocyte/glomerulus (range) 3.42.0 (0.1–8.4) 0.20.3 (0–1.0) 0.0001
Cortical interstitium monocyte/high power field (40) (range) 12.99.2 (7.0–36.2) 6.55.0 (1.0–22.8) 0.0030
T cells/glomerulus (range) 1.40.9 (0–3.0) 1.11.7 (0–6.9)
NS is not significant.
a C4d vs. ACR, t test
for the C4d group was 0.96 and 0.57, respectively, for merulus or two or more PTC PMNs per hpf than did
a mean MO/glomerulus 0 and 0.91 and 0.93, respec- those with ACR (C4d). In the present study, five (22%)
tively, for a mean MO/glomerulus 	1.0. Varying num- C4d biopsies and two (7%) C4d biopsies had an aver-
bers of PMN were observed in the glomeruli and CI age of one or more PMNs per glomerulus, but the differ-
PTC in all of the C4d and most of the C4d biopsies. ence was not significant. Two (9%) of the C4d biopsies
Cortical interstitial MO were present in all biopsies but and none of the C4d biopsies had an average of 2.0 or
they appeared more prominent in the C4d ones (Fig more PMNs per PTC.
1). In most of the immunostained sections, it could not A comparison of the C4d group to one expanded
be determined with confidence whether the CI CD68 by the addition of 10 serially selected allograft biopsies
cells were within or outside the PTC. Neutrophilic tubul- (from nine patients) showing acute tubular injury sec-
itis was observed in proportionately more C4d biopsies ondary to ischemia or calcineurin inhibitor toxicity re-
(35%) than in C4d ones (11%) but the difference was vealed no significant differences between the two groups
not significant. Most of the C4d (78%) and C4d with respect to the biopsy variables under study (data
(82%) biopsies showed varying numbers of glomerular not shown).
T cells. Intimal arterial fibrinoid necrosis of was observed
in one C4d and one C4d biopsy. None of the biopsies Clinical data
showed glomerular fibrinoid change. One C4d and one There were significantly more females in the C4d
C4d biopsy demonstrated focal glomerular capillary group (67%) than in the C4d one (21%) (
2  6.371,
thrombosis. Although focal interstitial medullary hemor- P  0.0116). The mean age of the recipients was similar
rhage was noted in 4 of 18 (22%) C4d biopsies in which
in both groups (C4d, 45.9  12.3 years; C4d, 48.5 
the medulla was present and in one of 18 (6%) C4d
10.8 years) The number of cadaveric, living-related and
biopsies with medulla, the difference was not significant.
living-unrelated donors was eight (53%), four (27%),Within the C4d group there were no significant differ-
and three (20%), respectively, for the C4d group andences between the subgroups with and without acute
11 (46%), eight (33%), and five (21%), respectively, forcellular interstitial rejection with respect to any of the
the C4d patients. Significantly more C4d patients hadvariables assessed (data not shown).
a second or third transplant (40%) than did the C4d
group (8%) (
2  3.901, P  0.0483). The C4d groupQuantitative analysis
had a significantly higher proportion (62%) of patientsThe results are summarized in Table 2. The C4d group
with a PRA 20% prior to transplantation than did theshowed significantly greater glomerular infiltration by
C4d group (12%) (
2  8.373, P  0.0038). An anti-both PMNs (P  0.0003) and MO (P  0.0001) than did
donor antibody determination at the time of rejectionthe C4d group. The mean number of PMNs in PTCs
was performed in only one AHR patient and this waswas significantly higher in the C4d biopsies than in the
positive. Monoclonal antilymphocyte antibody therapyC4d ones (P  0.0035). CI MO infiltration was signifi-
was used in 53% and 29% of C4d and C4d patients,cantly greater in the C4d group than in the C4d group
respectively. One C4d patient was treated for two re-(P  0.0030). The level of glomerular T-cell infiltration
jection episodes by plasma exchange with full response.was very similar in both groups. There was no significant
The one C4d patient treated by IVIG alone did notdifference between the two C4d subgroups (with and
respond to therapy. Twenty-eight percent of the rejec-without ACR) with respect to any of the above variables
tion episodes in the C4d group failed to respond either(data not shown).
fully or partially to antirejection therapy while none ofIn a previous study, Mauiyyedi et al [5] showed that
the C4d rejection episodes failed to respond (
2 a significantly higher proportion of cases with AHR
(C4d) had an average of one or more PMNs per glo- 5.956, P  0.0147).
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DISCUSSION result in a significant correlation is unknown. Further
study is needed to answer these questions.It has been proposed that a definite diagnosis of AHR
Previous biopsy studies have emphasized the signifi-requires the demonstration of circulating antidonor anti-
cance of glomerular and PTC PMN infiltration as mark-body and that the term “suspicious for AHR” be re-
ers for AHR [5, 10]. In the present investigation, glomer-served for cases in which the allograft biopsies demon-
ular and PTC PMNs were present in all of the C4dstrate the histologic and immunopathologic features of
biopsies and in significantly greater numbers than in theAHR, but circulating antidonor antibody either cannot
ACR (C4d) biopsies, in agreement with previous re-be detected or has not been tested for [5]. As antidonor
ports [5, 10], but the numbers were smaller than thoseantibody assessment was performed in only one C4d
presented in a previous publication [5]. Whereas Mauiy-patient in the present retrospective study, it is uncertain
yedi et al [5] detected 	2.0 PTC PMNs per hpf in 65%whether the other C4d cases had definite AHR or were
of biopsies from patients with AHR, only 9% of theonly suspicious for this entity. In view of the strong as-
C4d biopsies in the present investigation showed this.sociation of strong diffuse PTC C4d immunostaining in
Similarly, 	1.0 PMN per glomerulus was demonstratedallograft biopsies and circulating antidonor antibody
in 55% of AHR biopsies in the study of Mauiyyedi et al[5, 8], it is likely that most or all of the C4d patients
[5] but in only 22% of our C4d specimens. Possiblein the present study had AHR.
explanations of these discrepancies include differencesThe results of this investigation demonstrate for the
in recipient demographics and donor characteristics.first time that glomerular, and to a lesser extent CI, MO
Criteria for the diagnosis of AHR have recently beeninfiltration is closely associated with PTC C4d staining.
proposed [5]. These include (1) diffuse and strong PTCTrpkov et al [10] noted that transplant glomerulitis was
staining for C4d; (2) at least one of an average of 	2.0observed significantly more often in patients with AHR
PTC PMNs per hpf, arterial fibrinoid necrosis, or acutecompared to those with ACR but did not determine the
tubular injury; and (3) circulating antidonor antibody [5].cell type(s) involved. Similarly, Nickeleit et al [23] ob-
In view of the results of the present study, we propose
served a significant correlation between PTC C4d stain-
that transplant glomerulitis due to MO infiltration be
ing and transplant glomerulitis but did not elaborate on added to the list of histologic criteria described above [5].
the cell type(s) infiltrating the glomeruli. A very recent
study of the pathology of AHR did not evaluate the renal ACKNOWLEDGMENTS
biopsies for MO infiltration [5].
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